Navigation Links
CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution

La Jolla, CA (PRWEB) April 08, 2013

California Healthcare Institute (CHI) Vice President of State Government Affairs Eve Bukowski today provided testimony before the Senate Business, Professions and Economic Development Committee on the importance of notifying physicians when a patient’s biologic prescription has been substituted with a biosimilar drug.

Bukowski, who was diagnosed with stage-four colon cancer, spoke from personal experience and urged the committee to consider patients in the process.

“All of us with diseases treated with biologic medicines understand the instability of our health and the risks of side effects associated with our treatments. It’s a risk we are willing to take for the benefits we receive,” Bukowski said. “Informing the physician of a substitution is not only consistent with current pharmacist-physician interaction, it’s a simple precautionary step.”

Unlike their pharmaceutical counterparts, biotech drugs are made from living organisms and derive from more complex manufacturing processes involving sensitive fermentation and purification. Biosimilars are products “highly similar to” or “interchangeable” with a U.S. Food and Drug Administration-licensed biological product.

New legislation known as SB 598 and authored by Sen. Jerry Hill (D-San Mateo) would regulate the dispensing of biosimilars. It would require patient and physician notification of biosimilar substitution and that the full name and manufacturer be indicated on the medicine’s label.

“SB 598 recognizes that because biologic medicines are not the same as chemically-based generic medicines they need their own set of rules,” Bukowski said.

The committee also heard from Geoffrey Eich, executive director of regulatory affairs at Amgen.

California is known as the “birthplace of biotechnology,” where life-saving biologics such as Avastin and Epogen were developed. The state’s biopharmaceutical industry employs 42,886 people, more than any other state in the nation. The industry is responsible for producing innovative products for treating heart disease, cancer, diabetes, multiple sclerosis and Alzheimer’s disease that serve to benefit millions of patients in the United States and around the world.

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
2. Nerium New Hire - Vice President of US Operations
3. California Healthcare Institute Appoints Vice President-State Government Affairs
4. Archie Cullen Named President of BioReliance
5. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
6. BIOCOM Names Rick Fultz Vice President of Business Development
7. AMRI Promotes Takeshi Yura, Ph.D., to Vice President of Discovery and Development Services, Asia
8. Lou Paradise, President and Chief of Research, Topical BioMedics, Inc. Slated to Speak at Integrative Healthcare Symposium
9. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
10. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
11. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
Post Your Comments:
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
Breaking Biology News(10 mins):